# Coagulation Cascade and Thrombosis in Vascular Disease

## Primary Hemostasis

### Platelet Adhesion

When vascular injury occurs, the subendothelial collagen and von Willebrand factor (vWF) become exposed. Platelets adhere to these exposed elements primarily through the glycoprotein Ib-IX-V receptor, which binds to vWF, especially under conditions of high shear stress. Additionally, glycoprotein VI (GPVI) on platelets binds directly to collagen. This adhesion process triggers platelet activation, initiating the formation of a hemostatic plug.

### Platelet Activation

Upon activation, platelets undergo a shape change from a smooth discoid form to a spiculated shape with pseudopods, enhancing their ability to interact with other platelets and the vessel wall. They release contents from alpha granules, which include fibrinogen, vWF, factor V, platelet-derived growth factor (PDGF), and platelet factor 4 (PF4), as well as dense granules containing ADP, serotonin, and calcium. Platelets also synthesize thromboxane A2 (TXA2) via cyclooxygenase-1 (COX-1), a pathway inhibited by aspirin. ADP released from dense granules activates the P2Y12 receptor, which is the target of antiplatelet drugs such as clopidogrel, ticagrelor, and prasugrel. Activation of the glycoprotein IIb/IIIa receptor represents the final common pathway for platelet aggregation.

### Platelet Aggregation

Activated glycoprotein IIb/IIIa receptors bind fibrinogen, which cross-links adjacent platelets to form the initial platelet plug, often referred to as the "white thrombus." The platelet surface also exposes phosphatidylserine, providing a negatively charged phospholipid platform essential for the assembly of coagulation factor complexes, thereby linking primary hemostasis to secondary hemostasis.

## Secondary Hemostasis: Coagulation Cascade

### Cell-Based Model of Coagulation (Current Understanding)

The modern understanding of coagulation is best described by the cell-based model, which occurs in three overlapping phases. The initiation phase begins when tissue factor (TF)-bearing cells are exposed to blood, allowing TF to bind circulating factor VIIa. The TF-VIIa complex activates small amounts of factors X and IX. During the amplification phase, the small amount of thrombin generated activates platelets and coagulation factors V, VIII, and XI on the platelet surface. The propagation phase involves a large-scale thrombin burst on the activated platelet surface. The tenase complex (factor IXa-VIIIa) activates factor X, and the prothrombinase complex (factor Xa-Va) converts prothrombin to thrombin. This thrombin burst then converts fibrinogen into fibrin, stabilizing the clot.

### Traditional Pathway Model (Still Useful for Lab Test Interpretation)

Although the cell-based model has largely replaced the traditional cascade model for clinical understanding, the latter remains useful for interpreting laboratory coagulation tests. The intrinsic pathway, assessed by the partial thromboplastin time (PTT), involves factors XII, XI, IX, and X and is activated by contact with negatively charged surfaces. The extrinsic pathway, measured by the prothrombin time (PT) and international normalized ratio (INR), is initiated by tissue factor and factor VII. Both pathways converge on the common pathway, where factor X, in complex with factor V, converts prothrombin to thrombin, which then converts fibrinogen to fibrin. Factor XIII cross-links fibrin monomers to form a stable clot.

### Natural Anticoagulant Mechanisms

The body maintains a balance to prevent excessive clotting through several natural anticoagulant systems. Antithrombin III (AT III) is a serine protease inhibitor that inactivates thrombin, factor Xa, IXa, and XIa; its activity is enhanced approximately 1000-fold by heparin. The protein C/protein S system is activated when thrombin binds thrombomodulin on the endothelial surface, forming a complex that activates protein C. Activated protein C, with protein S as a cofactor, inactivates factors Va and VIIIa. Tissue factor pathway inhibitor (TFPI) inhibits the TF-VIIa-Xa complex, while heparan sulfate, a glycosaminoglycan on the endothelial surface, enhances AT III activity. Together, these mechanisms form a protective anticoagulant layer on the endothelium.

### Fibrinolysis

Fibrinolysis is the process that breaks down clots once they have served their purpose. Tissue plasminogen activator (tPA), released from endothelial cells, converts plasminogen into plasmin. Plasmin then degrades fibrin into fibrin degradation products (FDPs) and D-dimer fragments. This process is tightly regulated by plasminogen activator inhibitor-1 (PAI-1) and alpha-2-antiplasmin. Additionally, thrombin-activatable fibrinolysis inhibitor (TAFI) removes plasmin binding sites from fibrin, reducing fibrinolysis and stabilizing the clot.

## Virchow's Triad

### 1. Endothelial Injury / Dysfunction

Endothelial injury or dysfunction is the most critical factor in arterial thrombosis. Atherosclerotic plaque rupture or erosion exposes tissue factor and collagen, triggering coagulation. Other causes include surgical injury, catheter trauma, and inflammation. Such injury leads to loss of the endothelium’s natural antithrombotic properties, promoting thrombosis.

### 2. Stasis / Altered Blood Flow

Stasis or altered blood flow is the predominant factor in venous thrombosis. Conditions such as immobility, venous valve pockets, and aneurysmal dilation lead to blood flow stagnation. This allows activated clotting factors to accumulate and prevents their dilution and clearance by hepatic mechanisms, favoring clot formation.

### 3. Hypercoagulability

Hypercoagulability can be inherited or acquired. Inherited causes include Factor V Leiden mutation (the most common), prothrombin G20210A mutation, antithrombin III deficiency, and protein C or S deficiency. Acquired causes encompass malignancy, pregnancy, oral contraceptive use, antiphospholipid syndrome, heparin-induced thrombocytopenia (HIT), myeloproliferative disorders, and nephrotic syndrome.

| Category | Condition | Mechanism | Relative VTE Risk |
|----------|-----------|-----------|-------------------|
| Inherited | Factor V Leiden (heterozygous) | Resistance to activated protein C | 5–7x |
| Inherited | Factor V Leiden (homozygous) | Resistance to activated protein C | 50–80x |
| Inherited | Prothrombin G20210A | Elevated prothrombin levels | 2–3x |
| Inherited | Antithrombin III deficiency | Reduced thrombin/Xa inhibition | 10–50x |
| Inherited | Protein C deficiency | Reduced Va/VIIIa inactivation | 7–10x |
| Inherited | Protein S deficiency | Reduced protein C cofactor activity | 5–10x |
| Acquired | Antiphospholipid syndrome | Antibodies against phospholipid-binding proteins | 5–10x |
| Acquired | Malignancy | Tissue factor expression, stasis | 4–7x |
| Acquired | HIT | Anti-PF4/heparin antibodies | High (thrombosis paradox)  |  Depending on the specific condition, hypercoagulability can predispose to both arterial and venous thrombosis. |

## Arterial vs. Venous Thrombosis

### Arterial Thrombosis

Arterial thrombosis is characterized by platelet-rich clots, often called "white thrombi." It is typically triggered by endothelial disruption, such as plaque rupture, under conditions of high shear stress. Treatment focuses on antiplatelet agents like aspirin and P2Y12 inhibitors. Arterial thrombosis usually occurs at sites of atherosclerosis.

### Venous Thrombosis

Venous thrombosis involves clots rich in fibrin and red blood cells, known as "red thrombi." It is primarily triggered by stasis and hypercoagulability. Treatment relies on anticoagulants such as heparin, warfarin, and direct oral anticoagulants (DOACs). Venous thrombosis commonly occurs in deep veins, especially at valve cusps.

| Feature | Arterial Thrombosis | Venous Thrombosis |
|---------|--------------------|--------------------|
| Clot composition | Platelet-rich ("white thrombus") | Fibrin/RBC-rich ("red thrombus") |
| Primary trigger | Endothelial disruption (plaque rupture) | Stasis and hypercoagulability |
| Shear conditions | High shear stress | Low shear stress |
| Typical location | Sites of atherosclerosis | Deep veins, valve cusps |
| Treatment | Antiplatelet agents | Anticoagulants |
| Virchow's element | Endothelial injury | Stasis/hypercoagulability |

## Hypercoagulable States Relevant to Vascular Surgery

### Heparin-Induced Thrombocytopenia (HIT)

Type II HIT is an immune-mediated condition caused by antibodies against the platelet factor 4 (PF4)-heparin complex. It typically develops 5 to 10 days after heparin exposure, or sooner if there has been prior exposure. Despite thrombocytopenia, HIT paradoxically causes thrombosis rather than bleeding. Platelet counts drop by more than 50% from baseline. Diagnosis involves clinical scoring systems like the 4T score, anti-PF4/heparin ELISA, and the serotonin release assay, which is the gold standard. Treatment requires immediate cessation of all heparin products and initiation of alternative anticoagulation with agents such as argatroban or bivalirudin. Warfarin should not be started until platelet counts recover due to the risk of warfarin-induced venous limb gangrene caused by transient protein C depletion.

### Antiphospholipid Syndrome

Antiphospholipid syndrome is characterized by the presence of lupus anticoagulant, anticardiolipin antibodies, and anti-beta-2-glycoprotein I antibodies. It predisposes patients to both arterial and venous thrombosis as well as recurrent pregnancy loss. Although the partial thromboplastin time (PTT) is prolonged in vitro, the syndrome is prothrombotic in vivo. Long-term warfarin therapy is the treatment of choice, as direct oral anticoagulants (DOACs) have been shown to be less effective in this condition, according to the TRAPS trial.

### Factor V Leiden

Factor V Leiden is the most common inherited thrombophilia, affecting about 5% of Caucasians. It causes resistance to activated protein C, increasing the risk of venous thrombosis. Heterozygous individuals have a 5- to 7-fold increased risk of deep vein thrombosis (DVT), while homozygous individuals have a 50- to 80-fold increased risk.

## Thrombophilia Workup Indications

A thrombophilia workup is indicated in cases of unprovoked venous thromboembolism (VTE) in young patients under 50 years old, recurrent VTE, thrombosis in unusual sites such as mesenteric or cerebral veins, strong family history of thrombosis, and arterial thrombosis in young patients without traditional risk factors. Testing should be deferred until the patient is off anticoagulation because heparin affects antithrombin III levels, warfarin affects protein C and S levels, and DOACs can interfere with lupus anticoagulant testing.

<image>Comprehensive diagram of the cell-based coagulation model showing three phases: initiation on TF-bearing cells (TF-VIIa activating IX and X), amplification on the platelet surface (thrombin activating V, VIII, XI, and platelets), and propagation (tenase and prothrombinase complexes generating a thrombin burst converting fibrinogen to cross-linked fibrin). Use color-coding to distinguish the three phases.</image>

<image>Illustration of Virchow's triad as a Venn diagram with three overlapping circles labeled Endothelial Injury, Stasis, and Hypercoagulability. In each circle, list clinical examples. In the center overlap, show a thrombus. Adjacent to the diagram, show cross-sections comparing an arterial white thrombus (platelet-rich, at a plaque rupture site) and a venous red thrombus (fibrin and RBC-rich, in a valve pocket with stasis).</image>

<image>Illustration of natural anticoagulant mechanisms on the endothelial surface: thrombomodulin binding thrombin to activate protein C, antithrombin III enhanced by heparan sulfate inhibiting thrombin and Xa, tissue factor pathway inhibitor blocking TF-VIIa, and tPA release for fibrinolysis. Show these mechanisms as a protective layer on the endothelial surface with labeled arrows.</image>

## Key Clinical Pearls

The cell-based model of coagulation has largely supplanted the traditional cascade model for clinical understanding, though the cascade model remains essential for interpreting laboratory values such as PT/INR and PTT. Arterial thrombosis is primarily driven by platelets and is treated with antiplatelet agents, whereas venous thrombosis is driven by coagulation factors and requires anticoagulant therapy. Heparin-induced thrombocytopenia (HIT) is a prothrombotic condition despite thrombocytopenia; therefore, heparin must be stopped and anticoagulation continued with a non-heparin agent. Warfarin should never be initiated in acute HIT without alternative anticoagulation due to the risk of warfarin-induced venous limb gangrene caused by transient protein C depletion. Factor V Leiden is the most common inherited thrombophilia but mainly increases the risk of venous, not arterial, thrombosis. Antithrombin III is the primary target of heparin, and deficiency of AT III leads to heparin resistance. Finally, D-dimer, a fibrin degradation product, is useful for ruling out venous thromboembolism in patients with low clinical probability but is not diagnostic on its own.

## References
- Hoffman M, Monroe DM. A cell-based model of hemostasis. *Thromb Haemost*. 2001;85:958-965.
- Warkentin TE et al. Heparin-induced thrombocytopenia. *N Engl J Med*. 2015;373:252-261.
- Pengo V et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome (TRAPS). *Blood*. 2018;132:1365-1371.
- Bagot CN, Arya R. Virchow and his triad: a question of attribution. *Br J Haematol*. 2008;143:180-190.